These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 21453263)
1. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions. Shaikh SM; Avachat AM Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263 [TBL] [Abstract][Full Text] [Related]
2. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Dudhipala N; Veerabrahma K Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287 [TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Jain S; Reddy VA; Arora S; Patel K Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488 [TBL] [Abstract][Full Text] [Related]
4. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553 [TBL] [Abstract][Full Text] [Related]
5. Candesartan Cilexetil Formulations in Mesoporous Silica: Preparation, Enhanced Dissolution In Vitro, and Oral Bioavailability In Vivo. Guan H; Wang M; Yu S; Wang C; Chen Q; Chen Y; Zhang W; Fan J J Pharm Sci; 2024 Oct; 113(10):3045-3053. PubMed ID: 39094942 [TBL] [Abstract][Full Text] [Related]
6. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies. Ali ISM; Sajad UA; Abdul Rasool BK PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120 [TBL] [Abstract][Full Text] [Related]
7. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium. Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925 [TBL] [Abstract][Full Text] [Related]
8. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan. Chella N; Tadikonda R Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274 [TBL] [Abstract][Full Text] [Related]
9. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. Surampalli G; Nanjwade BK; Patil PA; Chilla R Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228 [TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and Amer AM; Allam AN; Abdallah OY Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678 [TBL] [Abstract][Full Text] [Related]
12. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408 [TBL] [Abstract][Full Text] [Related]
13. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. Ugurlu T; Nalbantoglu A; Sengel-Turk CT Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119 [TBL] [Abstract][Full Text] [Related]
14. Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs. Zhang L; Zhu W; Lin Q; Han J; Jiang L; Zhang Y Int J Nanomedicine; 2015; 10():3291-302. PubMed ID: 25995635 [TBL] [Abstract][Full Text] [Related]
15. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361 [TBL] [Abstract][Full Text] [Related]
16. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs. Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950 [TBL] [Abstract][Full Text] [Related]
17. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media. Hoppe K; Sznitowska M AAPS PharmSciTech; 2014 Oct; 15(5):1116-25. PubMed ID: 24871550 [TBL] [Abstract][Full Text] [Related]
18. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332 [TBL] [Abstract][Full Text] [Related]
19. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism. Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344 [TBL] [Abstract][Full Text] [Related]
20. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models. Surampalli G; K Nanjwade B; Patil PA Drug Dev Ind Pharm; 2015; 41(7):1057-65. PubMed ID: 24918161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]